9FX.F Zhaoke Ophthalmology Limited

Healthcare Biotechnology Frankfurt Exchange
0.2180 EUR
Close of Nov 11, 2026
0.1950 0.3760
Market cap
EUR 119M
P/E
-
P/B
0.64x
ROE
-13.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 9FX.F undervalued?

Graham number

The Graham number of Zhaoke Ophthalmology Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Zhaoke Ophthalmology Limited fundamental analysis

No fundamental analysis for Zhaoke Ophthalmology Limited yet.

Zhaoke Ophthalmology Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Zhaoke Ophthalmology Limited

Zhaoke Ophthalmology Limited operates as an ophthalmic pharmaceutical company in Hong Kong, Mainland China, South Korea, and internationally. The company develops Cyclosporine A ophthalmic gel for the treatment of dry eye disease (DED); RGN-259, an eye drop indicated for moderate-to-severe DED; CsA/rebamipide ophthalmic gel for anti-inflammation and tear film stabilization; and IC-265 in Phase II clinical trial for the treatment of allergic conjunctivitis. It also engages in…

Full company profile